2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Sarcoma
2
Dermatologic
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Paclitaxel
581
Carboplatin
528
Cisplatin
359
Bevacizumab
256
pembrolizumab
228
Gemcitabine
157
liposomal doxorubicin
132
Topotecan
131
olaparib
129
Cyclophosphamide
128
Radiotherapy
118
Taxes
114
Docetaxel
95
Brachytherapy
94
Drug Therapy
91
niraparib
88
Doxorubicin
86
Surveys and Questionnaires
85
Magnetic Resonance Spectroscopy
80
Blood Specimen Collection
74
Nivolumab
71
Specimen Handling
70
Hyperthermic Intraperitoneal Chemotherapy
64
Biopsy
63
fludarabine
57
Filgrastim
53
Letrozole
50
Oxaliplatin
49
durvalumab
47
Immunoglobulin G
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
tinostamustine
×
Gynecologic
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts